Radiotherapy-induced glioblastoma: distinct differences in overall survival, tumor location, pMGMT methylation and primary tumor epidemiology in Hong Kong chinese patients

References

• Smart D. Radiation toxicity in the central nervous system: mechanisms and strategies for injury reduction. Semin Radiat Oncol 2017;27:332–9.
   PubMed Web of Science ®Google Scholar
• Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006;98:1528–37.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Hayano A, Kanayama T. Radiation-induced gliomas: a comprehensive review and meta-analysis. Neurosurg Rev 2018;41:719–31.
   PubMed Web of Science ®Google Scholar
• Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354:34–9.
   PubMed Web of Science ®Google Scholar
• Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet 2016;387:1012–24.
   PubMed Web of Science ®Google Scholar
• Poynter JN, Fonstad R, Tolar J, Spector LG, Ross JA. Incidence of intracranial germ cell tumors by race in the United States, 1992-2010. J Neurooncol 2014;120:381–8.
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014;16:1263–73.
   PubMed Web of Science ®Google Scholar
• Cahan WG, Woodard HQ, Higinbotham NL, et al. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1948;1:3–29.
   PubMed Web of Science ®Google Scholar
• Ening G, Osterheld F, Capper D, Schmieder K, Brenke C. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J Cancer Res Clin Oncol 2015;141:1131–7.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
   PubMedGoogle Scholar
• Yonehara S, Brenner AV, Kishikawa M, et al. Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958-1995. Cancer 2004;101:1644–54.
   PubMed Web of Science ®Google Scholar
• Rahu M, Rahu K, Auvinen A, et al. Cancer risk among Chernobyl cleanup workers in Estonia and Latvia, 1986-1998. Int J Cancer 2006;119:162–8.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398–406.
   PubMed Web of Science ®Google Scholar
• Boice JD, Jr., Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988;116:3–55.
   PubMed Web of Science ®Google Scholar
• Prasad G, Haas-Kogan DA. Radiation-induced gliomas. Expert Rev Neurother 2009;9:1511–7.
   PubMed Web of Science ®Google Scholar
• Elsamadicy AA, Babu R, Kirkpatrick JP, Adamson DC. Radiation-induced malignant gliomas: a current review. World Neurosurg 2015;83:530–42.
   PubMed Web of Science ®Google Scholar
• Salvati M, D'Elia A, Melone GA, et al. Radio-induced gliomas: 20-year experience and critical review of the pathology. J Neurooncol 2008;89:169–77.
   PubMed Web of Science ®Google Scholar
• Paulino AC, Mai WY, Chintagumpala M, Taher A, Teh BS. Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys 2008;71:1381–7.
   PubMed Web of Science ®Google Scholar
• Adams H, Chaichana KL, Avendaño J, Liu B, Raza SM, Quiñones-Hinojosa A. Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2009. World Neurosurgery 2013;80:e237–e243.
   PubMed Web of Science ®Google Scholar
• Babu R, Sharma R, Karikari IO, Owens TR, Friedman AH, Adamson C. Outcome and prognostic factors in adult cerebellar glioblastoma. J Clin Neurosci 2013;20:1117–21.
   PubMed Web of Science ®Google Scholar
• Hong B, Banan R, Christians A, et al. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis. Acta Neurochir (Wien) 2018;160:2237–48.
   PubMed Web of Science ®Google Scholar
• Weber DC, Miller RC, Villa S, et al. Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2006;66:179–86.
   PubMed Web of Science ®Google Scholar
• Tsung AJ, Prabhu SS, Lei X, Chern JJ, Benjamin Bekele N, Shonka NA. Cerebellar glioblastoma: a retrospective review of 21 patients at a single institution. J Neurooncol 2011;105:555–62.
   PubMed Web of Science ®Google Scholar
• Larjavaara S, Mäntylä R, Salminen T, et al. Incidence of gliomas by anatomic location. Neuro Oncol 2007;9:319–25.
   PubMed Web of Science ®Google Scholar
• Ho CS, Beating '. Beating 'Guangdong cancer': a review and update on nasopharyngeal cancer. Hong Kong Med J 2017;23:497–502.
   PubMed Web of Science ®Google Scholar
• Feng M, Huang Y, Fan X, Xu P, Lang J, Wang D. Prognostic variables for temporal lobe injury after intensity modulated-radiotherapy of nasopharyngeal carcinoma. Cancer Med 2018;7:557–64.
   PubMed Web of Science ®Google Scholar
• Diallo I, Haddy N, Adjadj E, et al. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys 2009;74:876–83.
   PubMed Web of Science ®Google Scholar
• Daoud J, Ben Salah H, Kammoun W, et al. [Radiation-induced glioblastoma and myxoma after treatment for undifferentiated carcinoma of the naspharynx]. Cancer Radiother 2000;4:469–72.
   PubMedGoogle Scholar
• Lin K-C, Cheng T-J, Yung J-M, Kuo J-R. Malignant astrocytoma following radiation for nasopharyngeal carcinoma: case report and review of the literature. Acta Neurol Taiwan 2007;16:27–32.
   PubMedGoogle Scholar
• Villano JL, Propp JM, Porter KR, et al. Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries. Neuro Oncol 2008;10:121–30.
   PubMed Web of Science ®Google Scholar
• Makino K, Nakamura H, Yano S, Kuratsu J, Kumamoto Brain Tumor G, Kumamoto Brain Tumor Group. Population-based epidemiological study of primary intracranial tumors in childhood. Childs Nerv Syst 2010;26:1029–34.
   PubMed Web of Science ®Google Scholar
• Kim JY, Park J. Understanding the treatment strategies of intracranial germ cell tumors: focusing on radiotherapy. J Korean Neurosurg Soc 2015;57:315–22.
   PubMed Web of Science ®Google Scholar
• Hwang K, Lee KS, Choe G, Cho BG, Kim CY. Secondary glioblastoma after treatment of intracranial germinoma - would radiation-only therapy still be safe? Case report. BMC Cancer 2018;18:1119.
   PubMed Web of Science ®Google Scholar
• Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009;91:4–15. discussion 11–13.
   PubMed Web of Science ®Google Scholar
• Brat DJ, James CD, Jedlicka AE, et al. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol 1999;154:1431–8.
   PubMed Web of Science ®Google Scholar
• Donson AM, Erwin NS, Kleinschmidt-DeMasters BK, Madden JR, Addo-Yobo SO, Foreman NK. Unique molecular characteristics of radiation-induced glioblastoma. J Neuropathol Exp Neurol 2007;66:740–9.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Woo P, Ho J, Lam S, et al. A comparative analysis of the usefulness of survival prediction models for patients with glioblastoma in the temozolomide era: the importance of methylguanine methyltransferase promoter methylation, extent of resection, and subventricular zone location. World Neurosurg 2018;115:e375–e385.
   PubMed Web of Science ®Google Scholar
• Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 2018;233:378–86.
   PubMed Web of Science ®Google Scholar
• Margison GP, Santibanez-Koref MF. O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 2002;24:255–66.
   PubMed Web of Science ®Google Scholar
• Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 2009;29:3759–68.
   PubMed Web of Science ®Google Scholar
• Woo PYM, Li Y, Chan AY, et al. A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O‑6‑methylguanine‑DNA methyltransferase. Glioma 2019;2:68–82.
   Google Scholar
• Miousse IR, Kutanzi KR, Koturbash I. Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications. Int J Radiat Biol 2017;93:457–69.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A, et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 2010;12:283–8.
   PubMed Web of Science ®Google Scholar
• Park CK, Kim JE, Kim JY, et al. The changes in MGMT promoter methylation status in initial and recurrent glioblastomas. Transl Oncol 2012;5:393–7.
   PubMed Web of Science ®Google Scholar
• Christmann M, Nagel G, Horn S, et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 2010;127:2106–18.
   PubMed Web of Science ®Google Scholar
• Sminia P, Mayer R. External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain. Cancers (Basel) 2012;4:379–99.
   PubMedGoogle Scholar
• Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–22.
   PubMed Web of Science ®Google Scholar
• Efficace F, Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. Lancet Oncol 2003;4:11–2.
   PubMed Web of Science ®Google Scholar